AbbVie Inc. Q2 2026 Earnings Recap

AbbVie's shares declined 2.5% following Q2 earnings despite beatings in revenue and EPS, reflecting investor caution likely tied to ongoing biosimilar erosion in HUMIRA and mixed segment performance that tempered enthusiasm.

Key Takeaways

• Adjusted EPS came in at $3.65, $0.06 above guidance midpoint, with total net revenues nearly $17 billion, beating expectations by $300 million.
• Immunology sales grew 14.6% operationally to $8.8 billion, driven by SKYRIZI’s 24% growth and RINVOQ’s 23.7% growth; however, HUMIRA sales declined 36.1% due to biosimilar competition.
• Pipeline progress included FDA approval of Decnapaz and multiple European approvals (QLIPTA, Epkinly, Bowie, RINVOQ in derm conditions) with raised peak sales expectations for new indications.
• AbbVie announced acquisition of Apogee Therapeutics to deepen immunology pipeline, signaling focus on sustaining long-term growth.
• Despite revenue and earnings beats, the stock’s negative reaction suggests investor concerns around biosimilar impact and potentially cautious outlook on margin pressures or growth sustainability.